1
|
Banchereau J, Bazan F, Blanchard D, et al:
The CD40 antigen and its ligand. Annu Rev Immunol. 12:881–922.
1994. View Article : Google Scholar : PubMed/NCBI
|
2
|
Smith CA, Farrah T and Goodwin RG: The TNF
receptor superfamily of cellular and viral proteins: activation,
costimulation, and death. Cell. 76:959–962. 1994. View Article : Google Scholar : PubMed/NCBI
|
3
|
Paulie S, Ehlin-Henriksson B, Mellstedt H,
Koho H, Ben-Aissa H and Perlman BA: p50 surface antigen restricted
to human urinary bladder carcinomas and B lymphocytes. Cancer
Immunol Immunother. 20:23–28. 1985. View Article : Google Scholar : PubMed/NCBI
|
4
|
Aldderson MR, Armitage R, Tough TW,
Strockbine L, Fanslow WC and Spriggs M: CD40 expression by human
monocytes: regulation by cytokines and activation of monocytes by
the ligand for CD4. Exp Med. 178:669–674. 1993. View Article : Google Scholar : PubMed/NCBI
|
5
|
Caux C, Massacrier C, Vanbervliet B, et
al: Activation of human dendritic cells through CD40 cross-linking.
J Exp Med. 180:1263–1272. 1994. View Article : Google Scholar : PubMed/NCBI
|
6
|
Yellin MJ, Winikoff S, Fortune SM, et al:
Ligation of CD40 on fibroblast induces CD54 (ICAM-1) and CD106
(VCAM-1) up-regulation and IL-6 production and proliferation. J
Leukocyt Biol. 58:209–216. 1995.PubMed/NCBI
|
7
|
Zong YS, Lin H, Choy DTK, et al:
Nasopharyngeal carcinoma and lymphoinfiltration. Oncology.
48:290–296. 1991. View Article : Google Scholar : PubMed/NCBI
|
8
|
Galy AHM and Spitz H: CD40 is functionally
expressed on human thymic epithelial cells. J Immunol. 149:775–782.
1992.PubMed/NCBI
|
9
|
Pammer J, Weninger W, Mazal PR, Horvat R
and Tschachler E: Expression of the CD40 antigen on normal
endothelial cells and in benign and malignant tumours of vascular
origin. Histopathology. 29:517–524. 1996. View Article : Google Scholar : PubMed/NCBI
|
10
|
Armitage RJ, Fanslow WC, Stockbine L, et
al: Molecular and biological characterization of a murine ligand
for CD40. Nature. 357:80–82. 1992. View
Article : Google Scholar : PubMed/NCBI
|
11
|
Gauchat JF, Henchoz S, Mazzei G, et al:
Induction of human IgE synthesis in B cells by mast cells and
basophils. Nature. 365:340–343. 1993. View
Article : Google Scholar : PubMed/NCBI
|
12
|
Banchereau J, de Paoli P, Valle A, et al:
Long-term human B cell lines dependent on interleukin-4 and
antibody to CD40. Science. 251:70–72. 1991. View Article : Google Scholar : PubMed/NCBI
|
13
|
Liu YJ, Mason DY, Johnson GD, et al:
Germinal center cells express bcl-2 protein after activation by
signals which prevent their entry into apoptosis. Eur J Immunol.
21:1905–1910. 1991. View Article : Google Scholar : PubMed/NCBI
|
14
|
Choi MSK, Boise LH, Gottschalk AR,
Quintans J, Thompson CB and Klaus GGB: The role of bcl-xl-mediated
rescue from anti-μ-induced apoptosis in WEHI-231 B lymphoma cells.
Eur J Immunol. 25:1352–1357. 1995.
|
15
|
Ludewig B, Graf D, Gelderblom HR, Becker
Y, Kroczek RA and Pauli G: Spontaneous apoptosis of dendritic cells
is efficiency inhibited by TRAP (CD40-ligand) and TNF-α, but
strongly enhanced by interleukin-10. Eur J Immunol. 25:1943–1950.
1995.PubMed/NCBI
|
16
|
Tong AW, Papayoti MH, Netto G, et al:
Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous
expression in human breast cancer. Clin Cancer Res. 3:691–703.
2001.PubMed/NCBI
|
17
|
Costello A, Rey-Hipolito C, Patel A, et
al: Thyroid cancers express CD-40 and CD-40 ligand: cancers that
express CD-40 ligand may have a greater risk of recurrence in young
patients. Thyroid. 2:105–113. 2005. View Article : Google Scholar : PubMed/NCBI
|
18
|
Campean V, Neureiter D, Nonnast-Daniel B,
Garlichs C, Gross ML and Amann K: CD40-CD154 expression in
calcified and non calcified coronary lesions of patients with
chronic renal failure. Atherosclerosis. 190:155–166. 2007.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Yamada M, Shiroko T, Kawaguchi Y, et al:
CD40-CD40 ligand (CD154) engagement is required but not sufficient
for modulating MHC class I, ICAM-1 and Fas expression and
proliferation of human non-small cell lung tumors. Int J Cancer.
92:589–599. 2001. View
Article : Google Scholar : PubMed/NCBI
|
20
|
Ishikawa K, Miyamoto M, Yoshioka T, et al:
Up-regulation of CD40 with juxtacrine activity in human nonsmall
lung cancer cells correlates with poor prognosis. Cancer.
113:530–541. 2008. View Article : Google Scholar : PubMed/NCBI
|
21
|
Bajorath J, Seyama K, Nonoyama S, Ochs HD
and Aruffo A: Classification of mutations in the human CD40 ligand,
gp39, that is associated with X-linked hyper IgM syndrome. Protein
Sci. 5:531–534. 1996. View Article : Google Scholar : PubMed/NCBI
|
22
|
Fujimoto T, Nakamura T, Nishimura Y, et
al: Up-regulation of interleukin-12 receptor expression in
peripheral blood mononuclear cells of patients with
HTLV-I-associated myelopathy/tropical spastic paraparesis. J Neurol
Sci. 196:21–26. 2002. View Article : Google Scholar
|
23
|
Balashov KE, Smith DR, Khoury SJ, Hafler
DA and Weiner HL: Increased interleukin 12 production in
progressive multiple sclerosis: Induction by activated
CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA.
94:599–603. 1997. View Article : Google Scholar : PubMed/NCBI
|
24
|
Eriksson T, Frisk T, Gray SG, et al:
Methylation changes in the human IGF2 p3 promoter parallel IGF2
expression in the primary tumor, established cell line, and
xenograft of a human hepatoblastoma. Exp Cell Res. 270:88–95. 2001.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Hellings PW, Kasran A, Bullens D, et al:
IL-10- and IL-12-independent down-regulation of allergic
sensitization by stimulation of CD40 signaling. J Immunol.
177:5138–5144. 2006. View Article : Google Scholar : PubMed/NCBI
|